Elana J. Bernstein
Expertise in
8
conditions

Dr. Elana J. Bernstein

Internal Medicine | Rheumatology
161 Fort Washington Avenue, 
New York, NY 
Accepting New Patients
Offers Telehealth
Expertise in
8
conditions
161 Fort Washington Avenue, 
New York, NY 

Overview

Dr. Bernstein's clinical and research interests focus on systemic sclerosis (scleroderma), as well as on the detection and treatment of interstitial lung disease and pulmonary hypertension in patients with autoimmune diseases. She is the Florence Irving Associate Professor of Medicine at Columbia University Vagelos College of Physicians and Surgeons and an Associate Attending at NewYork-Presbyterian Hospital. Dr. Bernstein is the founder and Director of the Columbia University/NewYork-Presbyterian Scleroderma Center.Dr. Bernstein graduated summa cum laude from Amherst College, and was inducted into the Alpha Omega Alpha medical honor society while a medical student at the Mount Sinai School of Medicine. She was the recipient of the American College of Rheumatology Distinguished Fellow Award and the Charles L. Christian Award for Excellence in Musculoskeletal Research while a rheumatology fellow at Hospital for Special Surgery. In recognition of her outstanding contributions to systemic sclerosis research, Dr. Bernstein received the Edith Busch Prize for Young Investigators at the 8th Systemic Sclerosis World Congress. Dr. Bernstein has received grants from the National Institutes of Health, Department of Defense, Arthritis Foundation, and Rheumatology Research Foundation to study lung disease in scleroderma. Her ongoing research projects focus on interstitial lung disease in scleroderma and on lung transplantation in patients with autoimmune diseases.

Dr. Bernstein is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Systemic Sclerosis (SSc), Scleroderma, Scleredema, and Scleroma.

Dr. Bernstein is board certified in Internal Medicine and Rheumatology. She is actively involved in clinical research, co-authoring 103 peer reviewed articles and participating in 7 clinical trials. Dr. Bernstein is currently accepting new patients.

Residency

Massachusetts General Hospital

Specialties

Internal Medicine
Rheumatology

Licenses

Internal Medicine in NY

Board Certifications

Internal Medicine
Rheumatology

Fellowships

Hospital for Special Surgery

Hospital Affiliations

NewYork-Presbyterian / Columbia University Irving Medical Center
NewYork-Presbyterian Allen Hospital

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VNS Health
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 11 Less Insurance Carriers -

Locations

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue, New York, NY 10032

Additional Areas of Focus

Dr. Bernstein has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Scleroderma
Mixed Connective Tissue Disease
Vasculitis
Myositis
Polymyositis
Dermatomyositis

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Pilot Study Evaluating Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 3 Study Evaluating the Safety and Efficacy of Intravenous Iloprost in Subjects With Systemic Sclerosis Experiencing Symptomatic Digital Ischemic Episodes (AURORA Study)
Enrollment Status: Completed
Publish Date: May 25, 2025
Intervention Type: Drug
Study Drug: Iloprost
Study Phase: Phase 3
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
A Phase 2, Randomized, Placebo-controlled, Double-blind, Open-label Extension Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil (KD025) in Subjects With Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: August 30, 2023
Intervention Type: Drug
Study Drug: Belumosudil (KD025)
Study Phase: Phase 2
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
A Phase 2, Open-label Multicenter Study to Evaluate the Efficacy and Safety of Belumosudil in Subjects With Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Enrollment Status: Terminated
Publish Date: June 05, 2023
Intervention Type: Drug
Study Drug: Belumosudil
Study Phase: Phase 2
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
A Randomized, Double-Blind, Placebo-Controlled, Phase II Multicenter Trial of a Monoclonal Antibody to CD20 (Rituximab) for the Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Enrollment Status: Completed
Publish Date: February 21, 2023
Intervention Type: Other, Biological, Drug, Diagnostic test
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic Sclerosis
Enrollment Status: Terminated
Publish Date: March 29, 2021
Intervention Type: Drug, Other
Study Phase: Phase 3
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Enrollment Status: Completed
Publish Date: February 17, 2020
Intervention Type: Drug
Study Phase: Phase 2
View 6 Less Clinical Trials

103 Total Publications

A Common Missense Variant, W335S, in β2-Glycoprotein I (APOH) is Associated with Increased Autoantibody Levels but Reduced Venous Thromboembolism Risk.
A Common Missense Variant, W335S, in β2-Glycoprotein I (APOH) is Associated with Increased Autoantibody Levels but Reduced Venous Thromboembolism Risk.
Journal: medRxiv : the preprint server for health sciences
Published: March 23, 2026
Similar Doctors
Expertise in
19
conditions
Dr. Robert Spiera
Rheumatology
Expertise in
19
conditions
Dr. Robert Spiera
Rheumatology

Rheumatology Associates PC

1088 Park Ave, 
New York, NY 
 (4.2 miles away)
212-860-2100
Languages Spoken:
English
See accepted insurances

Robert Spiera is a Rheumatologist practicing medicine in New York, New York. Dr. Spiera is highly rated in 19 conditions, according to our data. His clinical expertise encompasses Systemic Sclerosis (SSc), Vasculitis, Rhizomelic Pseudopolyarthritis, and Polymyalgia Rheumatica.

Expertise in
17
conditions
Dr. Susan Goodman
Rheumatology
Expertise in
17
conditions
Dr. Susan Goodman
Rheumatology

Hospital For Special Surgery-Main Hospital

535 E 70th St Fl 6, 
New York, NY 
 (5.1 miles away)
212-606-1163
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Susan Goodman is a Rheumatologist practicing medicine in New York, New York. Dr. Goodman is highly rated in 17 conditions, according to our data. Her clinical expertise encompasses Rheumatoid Arthritis (RA), Arthritis, Psoriatic Arthritis, Knee Replacement, and Hip Replacement.

Expertise in
8
conditions
Dr. Anca Askanase
Rheumatology
Expertise in
8
conditions
Dr. Anca Askanase
Rheumatology

CUIMC/Herbert Irving Pavilion

161 Fort Washington Ave, 
New York, NY 
 (0.1 miles away)
929-445-7376
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Anca Askanase is a Rheumatologist practicing medicine in New York, New York. Dr. Askanase is highly rated in 8 conditions, according to our data. Her clinical expertise encompasses Systemic Lupus Erythematosus (SLE), Lupus Nephritis, Undifferentiated Connective Tissue Disease (UCTD), and Cutaneous Lupus Erythematosus (CLE).

Frequently Asked Questions about Dr. Elana J. Bernstein

How do I make an appointment with Dr. Elana J. Bernstein?

You can book an appointment with Dr. Elana J. Bernstein by calling their office at 212-305-4308. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Elana J. Bernstein a top-rated expert for Systemic Sclerosis (SSc)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Elana J. Bernstein is classified as an Elite expert for Systemic Sclerosis (SSc), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Elana J. Bernstein specialize in?

While Dr. Elana J. Bernstein is a Internal Medicine, they have specific expertise in Systemic Sclerosis (SSc), Scleroderma, and Scleredema. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Internal Medicine.

Does Dr. Elana J. Bernstein participate in research or clinical trials?

Yes. Dr. Elana J. Bernstein has published 103 articles and abstracts on conditions like Systemic Sclerosis (SSc). You can view a list of Dr. Elana J. Bernstein's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Elana J. Bernstein accept my insurance?

Dr. Elana J. Bernstein accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 212-305-4308 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Bernstein's expertise for a condition
ConditionClose
View All 15 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile